2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Weight Loss
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sleep Apnea Syndromes
1
Sezary Syndrome
1
Sarcoma
1
Recurrence
1
Overweight
1
Obesity, Morbid
1
Obesity
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hypertension
1
Hyperlipidemias
1
Hemangioma
1
Gastroesophageal Reflux
1
Eczema
1
Disease
1
Digestive System Diseases
1
Diabetes Mellitus, Type 2
1
Diabetes Mellitus
1
Dermatitis, Atopic
1
Collagen Diseases
1
Interventions
Blood Specimen Collection
9
Surveys and Questionnaires
6
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Prednisone
5
Mammography
5
Colonoscopy
5
Biopsy
5
Positron Emission Tomography Computed Tomography
4
Magnetic Resonance Imaging
4
Lenalidomide
4
Biopsy, Fine-Needle
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surgical Procedures, Operative
3
Melphalan
3
Liquid Biopsy
3
Interviews as Topic
3
Exercise
3
Diagnostic Tests, Routine
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Urination
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
Urine Specimen Collection
×
Clear all
NCT05151341
2025-07-24
URODX-FGFR3
Institut de Cancérologie de Lorraine
Phase NA
Completed
190 enrolled